Steroid Avoidance With Low-Dose Tacrolimus is Safe and Effective in the Long-Term for Kidney Transplant Recipients.

ABSTRACT:

Introduction

In our previous multicenter, open-label, randomized controlled trial (RCT), the SAILOR study, we reported good feasibility, safety, and efficacy of steroid avoidance (SA) at 2 years in immunologically low-risk kidney transplant recipients. A total of 222 participants were randomized to either antithymocyte globulin (ATG) induction + low-dose tacrolimus + mycophenolate mofetil (MMF) or basiliximab induction + low-dose tacrolimus + MMF + prednisolone. Long-term results are needed to confirm the extended safety and efficacy of the SA protocol beyond the short- to medium-term follow-up seen in current reports using low-dose tacrolimus.

Methods

In the SAILOR follow-up observational study, we collected clinical data of 215 participants of the original SAILOR trial at

SUBMITTER: Ekberg J 

PROVIDER: S-EPMC12446927 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature